US FDA issues 4 observations to Aurobindo Pharma arm's mfg unit in Telangana
This story was originally published at 16:52 IST on 27 February 2026
Register to read our real-time news.Informist, Friday, Feb. 27, 2026
--US FDA issues 4 observations to Aurobindo Pharma arm mfg unit in Telangana
MUMBAI – The US Food and Drug Administration has issued four observations to a Telangana facility of Eugia Pharma Specialities Ltd., a wholly-owned subsidiary of Aurobindo Pharma Ltd. The US regulator had inspected the manufacturing facility between Feb. 16 and Feb. 27.
Aurobindo Pharma intends to reply to the US regulator within the stupulated time. For the quarter ended December, it had reported consolidated net profit of INR 9.10 billion and revenue of INR 86.46 billion. End
Reported by Anshul Choudhary
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
